Plaque Psoriasis

Secukinumab is the only fully human biologic that directly inhibits IL-17A.

While Janus Kinase inhibitors are a fraction of what’s to come in dermatology, research from AAD VMX 2021 shows they represent the potential of unlocking new capabilities across the field.

Jeffrey Stark, MD, of UCB discusses the promising data being generated by the robust trial program for plaque psoriasis.

The Head of Immunology Medical Affairs at UCB discusses what bimekizumab is and how it works.

New cross-sectional survey data suggest quality-of-life and psychological outcomes may differ in the most common chronic skin disease patient populations.

Patients who received ixekizumab achieved PASI 90 at a median of 43.0 days and PASI 100 at 85.0 days.

In a Q&A, Peter Lio, MD, discusses some evidence for using integrative therapies with patients.

Rebecca Kazin, MD, offers some insight into her cosmetic dermatology practices, including a new hair product that she developed.

A comparison of the IL-17 inhibitors suggest the more dynamic pathway-targeting biologic is more efficacious, but linked to more oral candidiasis.

Valerie Callender, MD, draws on her experiences in clinical practice to discuss cosmetic dermatology care practices and the challenges of this past year.

The study underscores the importance of interpreting patient-reported disease severity scores in the context of mental health factors.

Two studies demonstrated that the IL-17A and IL-17F inhibitor can lead to superior levels of skin of clearance in adult patients compared with ustekinumab or placebo. .

Todd Schlesinger, MD, talks new therapies on the horizon and those that have already proven efficacious.

The FDA approvals of biologics for atopic dermatitis and psoriasis have ushered in a new era for the once-stagnant field of pediatric dermatology.

There is a gap between the efficacy of biologics in trials and the real-world setting.

Strict avoidance of systemic corticosteroids among patients with psoriasis may be unnecessary.